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Introduction
Status Epilepticus (SE) is a condition manifested with frequent seizures without 
recovering consciousness in between or is so prolonged that it can lead to a fixed 
and lasting condition in a comatose or confused state. Although any type of seizure 
can be presented as SE, the most common form is convulsive generalized Tonic-
Clonic Status Epilepticus (GTCSE) which is characterized by repeated generalized 
seizures, without gaining consciousness or by confusion for few hours or days(1). 
SE is a medical emergency that requires prompt diagnosis and appropriate treatment. 
In children GTCSE may be continuous and can lead to systemic cardiovascular 
dysfunction such as tachycardia, bradycardia and cardiac arrhythmia secondary to 
hyperkalemia. Using Phenobarbital and phenytoin or their metabolites may cause 
cardiac arrhythmia or hypotension. There may be respiratory failure either due to 
status epilepticus or use of Phenobarbital and benzodiazepines at times, altered lymph 
flew may induce pulmonary edema and renal failure secondary to rhabdomyolysis 
& myoglobinuria.
Other metabolic complications such as respiratory & metabolic acidosis, anoxia 
hyponatremia, hyperazothemia and hyperglycemia followed by hypoglycemia may 
occur.
Autonomic storm causing hyperpyrexia, profuse sweating, salivary and tracheo-
bronchial hypersecretion, cerebral complication, hyperthermia, cerebral edema, 
raised intracranial pressure, neuronal damage & cortical vein thrombosis. 
Endocrine abnormalities like elevation of prolactine GH(Growth Hormone) & ACT
H(Adrenocorticothropic Hormone) may be seen. There may be pleocytosis of CSF 
attributable to SE.
Treatment of convulsive status epilepticus can be divided into three steps:
1. Support of respiration and blood pressure and prevention of systemic 
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complications.
2. Treatment of seizure activity and prevention of seizure 
recurrence.
3. Identification of etiology and the precipitating factors 
that lead to SE.
The first step in support is to check the airway and 
cardiac output.
The patient should be positioned on his side with head 
down slightly to promote drainage of secretion & prevent 
aspiration; a soft object being placed beneath the head, 
helps to prevent injury.
History
Calmeil (1824) first used the expression  eta demal (Status 
Epilepticus), which at present is called Generalized 
Tonic-Clonic Epilepticus (GTCSE); it occurs in rapid 
succession without recovery between convulsions. SE is 
relatively more frequent in infants and young children, it 
is seen within the first year of life in about 30% of cases 
and before the age of 3 in 60%-70% of cases (1).
The seizures are mostly generalized. In fact under the 
age of 4 years, they are secondarily generalized or purely 
unilateral and can shift from side to side in the course of 
the same episode.
The tonic form of SE is an infrequent, erratic motor 
seizure observed only in newborns. SE is the first 
manifestation of epilepsy in three-fourths of cases. 50% 
of cases occur followed by acute brain injury such as 
meningitis encephalitis, severe dehydration, metabolic 
disorders, acute anoxic injury in children with cerebral 
palsy and non-progressive chronic encephalopathy(2).
Epidemiology
SE occurrence ranges from 1.3 to 6.6% of epileptics, 
manifesting usually as symptomatic epilepsy. Precipitants 
could be anti-epileptic withdrawal and/or non-
compliance, anti-epileptic interaction and resistance, 
trauma, hormonal change, emotional stress, progressive 
cerebral disease, sleep deprivation and febrile illness. 
Approximately 1% of patients with epilepsy will have 
an episode of SE in any given year (3).
Causes and Mechanism
Any brain injury or infection, structural or metabolic 
derangements, toxicity or chronic epilepsy may trigger 
SE.
Several mechanisms that terminate seizures, have 
been postulated. In children, the most common causes 
of SE are febrile convulsion. Meningitis, encephalitis, 
birth injury and degenerative neurological disorders 
due to seizures are common with any cortical lesion; in 
fact it is postulated that any defect in the mechanisms 
that terminate seizures, contributes to SE. One of the 
mechanisms in terminating seizures is the failure of 
astrocytes to regulate extra cellular K+. There could also 
be a deficit of γ-aminobutiric acid (GABA) inhibition. 
After a seizure depolarizing neurons cause increase in 
extra cellular K+. Astrocytes buffer extra cellular K+ 
via sodium potassium ATPase. And sodium –potassium 
ATPase lowers extra cellular K+ by increasing 
intracellular K+ within glia.
Normally after a seizure, sodium potassium ATPase’s 
activity increases; however after brain injury reduced, 
sodium potassium ATPase’s activity, rendering glia 
less able to manage the accumulation of extra cellular 
K+. For the GABA mechanism, it is well established 
that GABA receptor, modulates the inhibitory chloride 
channel. Activation of the GABA receptor increases the 
movement of the chloride in to the neuron causing hyper 
polarization of the membrane, thus making the neuron 
less susceptible to activation.
Proconvulsant agents which block or inhibit the GABA 
receptor, decrease chloride influx and move the resting 
membrane closer to activation. Prolonged seizures cause 
functional changes in the GABA receptors, rendering 
them progressively less sensitive to GABA and 
benzodiazepine over time. Excitoxicity plays a definite 
role in SE induced neuronal death. Glutamate receptors 
are heavily distributed in the hypocampus. Repetitive 
seizures and SE cause an increased release of Glutamate 
at presynaptic terminals which in turn produce selective 
post synaptic neuronal death. With activation of post-
synaptic NMDA an AMP A-kainite receptor increase 
sodium calcium influx into neurons which results in a 
swelling of the cytoplasm and cytoplasmic organelles 
especially mitochondria; the neuronal nitric oxide 
syntethase is activated, resulting in excessive production 
of nitrous oxide, which in turn generates free radicals 
that damage cellular proteins(4).
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Risk factors
• History of SE
• Structural or metabolic insult
• Drug interaction
• Lack of compliance
• Medication withdrawal, AEDs, Hypnotic, BZD, 
sedative
• Infection and autoimmune diseases
• Sleep deprivation and physical / emotional stress
Prognosis
Mortality ranges from 10-50% and increases with age.
Poor prognostic factors
• Advanced age
• Duration of SE
• Anoxia
• Stroke
• Central Nervous System infection
• Severe metabolic derangements
• Hypotension




Status Epilepticus has been described as a series of 
major motor seizures without recovery of consciousness 
between seizures. This fails to include many cases of 
focal and non-convulsive status and the majority of 
cases in infants. There is no general agreement on the 
duration of seizures sufficient to produce this fixed and 
prolonged condition. SE may occur de novo but also 
may be associated with clinical and/or neurological 
conditions like acute bacterial meningitis, encephalitis, 
intracranial abscess, intracranial tumor or metastasis, 
stroke, arteriovenous or cavernous malformation.
Also hypoglycemia, hyperglycemia, hyponatremia, 
acute intermittent porphyria, drugs or alcohol abuse or 
withdrawal, change of anti-epileptic drugs, preeclampsy, 
use of intravenous contrast agents or electroconvulsive 
therapy, and lastly idiopathic have been implicated in 
causing SE. Needless to say that for each of the above 
mentioned conditions, the approach for management 
and therapeutic interventions are different. 
Any lapse or delay in aggressive control of seizure 
activity is associated with high morbidity and morality. 
Thus rapid termination of seizures with simultaneous 
treatment of underlying illness is of utmost priority in the 
handling of TCSE patients. SE, lasting one hour or more, 
increases morbidity tenfold. Furthermore, although very 
rare, death may be a consequence of SE, soon after acute 
presentation.
Neurogenic pulmonary edema or life threatening cardiac 
arrhythmia and more likely prolonged apnea, anoxia 
may result persistent coma or death. 
As stated above, concurrent destructive lesions of 
brain are common in adult SE and thus, in most, are 
responsible for morbidity and mortality. As estimated 
125000 to 195000 episodes of SE occur in the USA 
annually, resulting in 22000 to 42000 deaths. Despite its 
improvement in medical management the incidence of 
morbidity and mortality still remain high.
For prevention of aspiration during transportation of 
patients with frequent seizure, the patient should have 
a nasogastric tube and the stomach contents must be 
suctioned before transfer. Any injuries sustained during 
seizures are a result of neglect in the immediate care 
given following a generalized seizure.
An evaluation must be made for post ictal injuries like 
humeral neck, femoral trochanter, clavicule and ankle 
fracture.
Fractures unrelated to seizure are 6 times greater in 
epileptics than in the general population especially 
between the ages of 45-64(2,3,4).
Serious head injuries like depressed fracture, intracerebral 
hemorrhage, subdural hematoma, epidural hematoma 
and aspiration during seizure should also be considered.
In patients with repetitive seizures or continuous clinical 
or electrical seizure activity with incomplete neurological 
recovery interictally for a period of at least 30 minutes, 
status epilepticus must be considered and the patient 
should be treated accordingly.
The best way for preventing morbidity and mortality in 
any patient having continuous seizure for 10 minutes or 
longer is to treat him/her for SE; in addition, impending 
SE should be suspected in patients experiencing three or 
more T-C seizure within a 24 hour period, particularly 
when this represents an increase from the typical 
frequency. SE is classified as a generalized or partial 
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Fig 1: Classification of status epilepticus (Wijdicks, 2000:56)
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Epilepticus













(focal), convulsive and non-convulsive in adults; the 
most common type of SE is secondary generalized 
convulsive status (GCSE), which if prolonged, gives way 
to increasing subtle clinical manifestations. Occasionally 
subtle SE occurs without prior convulsive activity in a 
patient with severe diffuse cerebral dysfunction. Acute 
CNS insult such as anoxia, head injury, stroke, neoplasm 
and infection account for 50% of cases.
Convulsive status epilepticus can be divided into four 
major categories and nonconvulsive status epilepticus 
can be further divided into complex partial and absence 
types (Figure.1).
In children most common precipitants are fever and 
infection, whereas cerebovascular disease is more 
prominent in older adults. Approximately 20% of all 
SE cases occur in epileptic patients during medication 
adjustment or noncompliance; in one third of patients, 
the cause of SE remains undetermined.SE should be 
suspected in patient with unexplained coma, with or 
without motor manifestations. Non-epileptic phenomena, 
including tremors, myoclonic and nystagmoid eye 
movement, oral or buccal  movements frequently occur 
following anoxia, brain stem or bilateral cerebral ischemia. 
Severe metabolic and electrolyte disturbances may be 
difficult to differentiate clinically from non convulsive 
status epilepticus. Occasionally prolonged psychogenic 
seizure are misinterpreted and treated as SE.
movements such as peddling or stepping and repetitive 
facial movements may not be suggested as a seizure for 
a physician who does not know the ropes. Additional 
problems are the frequent occurrence of epileptiform 
activity on the EEG without clinical manifestations 
and often an obtunded or comatose state of the child at 
most risk for seizure. For this reason, Aicardi & Chevire 
(1970) recommended listing recurrent neonatal seizures 
as serial seizure and not true SE. It should be noted that 
EEGs are essential in diagnosing SE in the newborns. 
There may be a slow spike and wave pattern or rhythmic 
alpha like discharges; a variety of different patterns 
may be seen on the same recording. These discharges 
are almost invariably focal with only rare generalized or 
bilaterally synchronous discharges. The supportive care 
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Status Epilepticus in Neonates
Neonatal SE has been defined by Dreyfus-Brisac & 
Monod (1964) as the repetition of clinical or even sub 
clinical seizures which occur for at least a few hours. Its 
recognition poses major difficulties in infants as stated  by 
Dreyfus-Brisac & Monod (5,6). The seizures are clonic 
episodes with limited distribution. There may be tonic 
episodes with posturing and rotation of head and eyes. 
Eye opening, blinking and nystagmous, abnormal crying 
and vasomotor changes other rhythmic movements of 
extremities, random myoclonic movements, organized 
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for a neonate with SE is similar to that given to the older 
child.
SE in infancy is almost always due to an acute 
encephalopathy. Glucose, Calcium and electrolytes 
should always be checked. Asphyxia is apparent from 
the history and initial examination. Most of these infants 
require a lumbar puncture to rule out acute meningitis. 
If the etiology is not otherwise apparent, metabolic 
screening, toxicology and neuro-imaging for congenital 
malformations are essential. In addition the child should 
receive 100 mg pyridoxine intravenously, best given 
with EEG monitoring. This should result in prompt 
normalizing of the EEG if the infant has pyridoxine 
deficiency or dependency(7).
Therapy of neonatal SE depends initially on diagnosis. 
Phenobarbital is the drug of choice for stopping neonatal 
seizures with serum concentration of 40 µg/ml. With this 
approach, 77% of seizures are controlled. If Phenobarbital 
is not successful, phenytoin is used as a second drug 
with 20 mg/kg loading dose and maintenance of 4-5 
mg/kg/day must be given IV since drug is not absorbed 
consistently from the neonatal GI tract. If neither of 
these drugs are effective, other agents to consider include 
Benzodiazepine, Primidone and Sodium Valporate. The 
prognosis for neonatal SE is guarded due to underlying 
etiologies.
Differential Diagnosis of Status Epilepticus
I. Convulsive status epilepticus
Generalized Convulsive Status Epilepticus (GCSE) can 
be seen in psychogenic seizures and unusual presentation 
of movement disorders (Myoclonus, Tremor and 
Chorea)(8).
1. Psychogenic spells can be extremely difficult to 
distinguish from epileptic seizures and there are many 
case reports of unnecessary intubation and medication 
induced coma. Even an experienced Epilepsy specialist 
may need to use video-EEG monitoring.
2. Movement disorders, not affecting consciousness, 
although a number of diseases can cause both movement 
disorder and seizures; for example Creutzfeld Jacob 
disease (CJD). Hyperactive reflexes and sustained 
posture, seen in stroke and hypoxia victims, can resemble 
seizures, as can hypocalcemic tetany.
II. Non convulsive status epilepticus
Basically the differential form of altered mental status 
includes
1. Trauma: Concussion, Intracranial hemorrhage, 
Intracranial Hypertension
2. Infectious: Meningo-encephalitis
3. Toxic: Drug overdose, poisoning 
4. Metabolic: Electrolytes’abnormalities(especia
lly hypernatremia), hypoglycemia, hypoxia, 
hypercarbia
5. Organ failure: Liver failure, respiratory failure, renal 
and cardiac failure, thyroid and adrenal disorders
6. Psychiatric: Fuge states, psychogenic spells, 
malingering
7. Others: Cerebral Vasculitis
Management of Status Epilepticus
Step I) Assess Airway, Breathing and Circulation
• Administer O2, Monitor Cardiac rhythm, O2 
saturation and vital signs
• Bedside glucose test
• Draw blood for AEDs , Hematologic chemistries, 
toxicological screens, Establish intravenous line 
with normal saline
• Thiamine 100mg and dextrose (50%) 50ml 
intravenous (DW 25% 2ml/kg in children)
• Obtain history and perform examination
Step II) Administer intravenous Diazepam 0.25 mg/kg 
in adults,0.1mg/kg in children) (Up to 5 mg/min) or 
Lorazepam (0.1mg/kg in adults, 0.05- 0.5 mg/kg in 
children) (up to 2 mg/min) repeat once if seizures 
persist.
 Simultaneous administration of phenytoin 20 mg/kg 
load (up to 50 mg/min in adults and 1 mg/kg/min in 
children or patient< 50 kg) or Fosphenytoin 15-20 
mg/kg (up to 150 mg/min) if seizure persists give 
PHT 5 mg/kg up to 30 mg/kg to level of 30 µg/ml)
Step III) Intubate, place arterial line and draw ABGs
• Phenobarbital 20 mg/kg loading with the rate of 
50-100 mg/kg/min in children.
• Generalized anesthesia with Midazolam 0.2 mg/kg 
loading dose followed by infusion at 0.1-0.4 mg/
kg/hr or Propofol 2 mg/kg/hr.
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Table 1: Management of Generalized Tonic-Clonic Status Epilepticus in children ( 12,13,14)
 




• Verify diagnosis of Status epilepticus. Monitor cardio respiratory function. ECG, pulse 
oximetry, and stabilize. EEG if possible. Insert oral airway, administer oxygen if needed, Insert 
i.v. catheter with normal saline solution. Draw AED levels, glucose, electrolytes, calcium, 
magnesium, BUN, CBC, arterial blood gas.
5 minutes • Start i.v. normal saline solution. Administer 50% glucose at 2 ml/kg.
10-30 minutes
• i.v. lorazepam, 0.1 mg/kg, at 1-2 mg/min to maximum of 5 mg. Start i.v. fosphenytoin 20 mg 
kg infused at 150 mg/min (or i.v. phenytoin 18-20 mg/kg, at a rate not to exceed 1 mg/kg per 
minute or 50/mg/min) with ECG and blood pressure monitoring; additional 10 mg/kg may be 
given after ward monitoring.
31-60 minutes
• If seizures persist, administer i.v. Phenobarbital at a rate not to exceed 50 mg/min until 
seizures stop or to a loading dose of 20 mg/kg.
>60 minutes
• If seizures persist, options include: (1) i.v. diazepam- continuous infusion, 50 mg diluted 
in 250 ml normal saline solution or D5W at 1 ml/kg/hour (2mg/kg/hour) to achieve blood 
levels of 0.2-0.8 mg/ml. (2) i.v. pentobarbital – initial loading dose of 5 mg/kg followed by 
maintenance infusion of 1-3 mg/kg/hour (with EEG monitoring) to produce burst suppression 
pattern on EEG. Decrease infusion rate 4-6 hours later to check for reappearance of seizures. 
If seen, repeat procedure. If not, taper over 12- 24 hours.
• If seizures are not controlled, ask an anesthesiologist to institute general anesthesia ith 
halothane and neuromuscular blockade.
ECG: electrocardiogram                            BUN: blood urea nitrogen
EEG: electroencephalography                    CBC: complete blood cell count
i.v.: intravenous                                        PE: phenytoin
AED: antiepileptic drug                             D5W: 5% dextrose in water
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 Step IV) If seizures persist, consider pharmacological 
coma with Pentobarbital 5-8 mg/kg loading, 
followed by maintenance 2-4 mg/ kg/hr titrated to 
burst suppressive for 6-48 hours (Pentobarbital level 
24-45 µg/ml)(9).
Treatment Protocol for SE with PENTOBARBITAL 
COMA (Setting ICU, Intubation, EEG monitoring):
Nonconvulsive SE when documented by EEG can be 
controlled under electro-encephalographic monitoring 
with Benzodiazepine (10,11). The management of 
SE in patient with pre-eclampsia is notably different. 
The management of Generalized Tonic-Clonic Status 
Epilepticus is presented in Table 1 and figure 2.
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Fig 2: Algorithm for management of convulsive status epilepticus
A: adult dose      IV: intravenous
BP: Blood pressure     P: Pediatric dose
IMV: Intermittent mandatory ventilation   WBC: White blood cells
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